PAVmed (PAVM) has a collection of products that are in various states of regulatory clearance, but taken together these have a market opportunity in the billions of dollars.
While good progress has been made, the company's immediate commercialization efforts for three of its products (EsoGuard and EsoCheck and CarpX) has been hampered by the suspension of non-essential procedures and the suspension of clinical trials for additional uses of these and some of its other products. We still think the shares are very interesting here, despite the obvious risks.
We described the company's products